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A B S T R A C T
Background
Colloid solutions are widely used in fluid resuscitation of critically ill patients. There are several choices of colloid and there is ongoing
debate about the relative effectiveness of colloids compared to crystalloid fluids.
Objectives
To assess the effects of colloids compared to crystalloids for fluid resuscitation in critically ill patients.
Search strategy
We searched theCochrane InjuriesGroupSpecialisedRegister, CENTRAL (The Cochrane Library2008, Issue 3),MEDLINE,EMBASE,
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED), ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S), and The Controlled Trials metaRegister (www.controlled-trials.com). Reference lists of relevant studies and
review articles were searched for further trials. The searches were last updated in September 2008.
Selection criteria
Randomised controlled trials (RCTs) of colloids compared to crystalloids, in patients requiring volume replacement.We excluded cross-
over trials and trials in pregnant women and neonates.
Data collection and analysis
Two authors independently extracted data and rated quality of allocation concealment. We analysed trials with a ’double-intervention’,
such as those comparing colloid in hypertonic crystalloid to isotonic crystalloid, separately. We stratified the analysis according to
colloid type and quality of allocation concealment.
Main results
We identified 65 eligible trials; 56 of these presented mortality data.
Colloids compared to crystalloids
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Albumin or plasma protein fraction - 23 trials reported data on mortality, including a total of 7754 patients. The pooled relative
risk (RR) from these trials was 1.01 (95% confidence interval (95% CI) 0.92 to 1.10). When we excluded the trial with poor quality
allocation concealment, pooled RR was 1.00 (95% CI 0.91 to 1.09).
Hydroxyethyl starch - 17 trials compared hydroxyethyl starch with crystalloids, n = 1172 patients. The pooled RR was 1.18 (95% CI
0.96 to 1.44).
Modified gelatin - 11 trials compared modified gelatin with crystalloid, n = 506 patients. The pooled RR was 0.91 (95% CI 0.49 to
1.72).
Dextran - nine trials compared dextran with a crystalloid, n = 834 patients. The pooled RR was 1.24 (95% CI 0.94 to 1.65).
Colloids in hypertonic crystalloid compared to isotonic crystalloid
Eight trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1283 randomised participants. Pooled RR
was 0.88 (95% CI 0.74 to 1.05).
Authors’ conclusions
There is no evidence from RCTs that resuscitation with colloids reduces the risk of death, compared to resuscitation with crystalloids,
in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival, and as they are
more expensive than crystalloids, it is hard to see how their continued use in these patients can be justified outside the context of RCTs.
P L A I N L A N G U A G E S U M M A R Y
No evidence that colloids are more effective than crystalloids in reducing mortality in people who are critically ill or injured
Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein)
to replace lost blood, is used to try to maintain blood pressure and reduce the risk of dying. Blood products, non-blood products
or combinations are used, including colloid or crystalloid solutions. Colloids are increasingly used but they are more expensive than
crystalloids. The review of trials found no evidence that colloids reduce the risk of dying compared with crystalloids.
B A C K G R O U N D
Fluid resuscitation for hypovolaemia is a mainstay of the med-
ical management of critically ill patients, whether as a result of
trauma, burns, major surgery or sepsis. Although recent studies
(Bickell 1994) have suggested that the timing of volume replace-
ment deserves careful consideration, when it comes to selecting
the resuscitation fluid, clinicians are faced with a range of options.
At one level the choice is between a colloid or crystalloid solution.
Colloids are widely used, having been recommended in a number
of resuscitation guidelines and intensive care management algo-
rithms (Armstrong 1994; Vermeulen 1995).
The US Hospital Consortium Guidelines recommend that col-
loids are used in haemorrhagic shock prior to the availability of
blood products, and in non-haemorrhagic shock following an ini-
tial crystalloid infusion. A 1995 survey of US academic health
centres, however, found that the use of colloids far exceeded even
the Hospital Consortium recommendations (Yim 1995). Surveys
of burn care in the US (Fakhry 1995) and in Australia (Victorian
DUAC 1991) found that the use of colloids for resuscitation var-
ied without a set pattern.
The choice of fluid has considerable cost implications. Volume re-
placement with colloids is considerably more expensive than with
crystalloids. Clinical studies have shown that colloids and crys-
talloids have different effects on a range of important physiolog-
ical parameters. Because of these differences, all-cause mortality
is arguably the most clinically relevant outcome measure in ran-
domised trials comparing the two fluid types.
Why it is important to do this review
Although there have been previous meta-analyses of mortality in
randomised trials comparing colloids and crystalloids (Bisonni
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1991; Velanovich 1989), neither of these satisfy the criteria that
have been proposed for scientific overviews (Oxman 1994), and
they predate most of the trials that have been conducted using syn-
thetic colloids, and hypertonic crystalloid solutions. The purpose
of this systematic review is to identify and synthesise all available
unconfounded evidence of the effect on mortality in critically ill
patients of colloids compared to crystalloids for volume replace-
ment.
O B J E C T I V E S
To assess the effects on mortality of using colloids compared to
crystalloids, during fluid resuscitation in critically ill patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Controlled trials in which participants were randomised to treat-
ment groups (colloid or control) on the basis of random alloca-
tion. As the comparison between fluid type was in terms of effects
on mortality, we excluded randomised cross-over trials.
Types of participants
Critically ill patients (excluding neonates) who required volume
replacement.We included patients whowere critically ill as a result
of trauma, burns, were undergoing surgery, or had other critical
conditions such as complications of sepsis.
We excluded pre-operative elective surgical patients.
Types of interventions
We considered the following colloids: Dextran 70, hydroxyethyl
starches, modified gelatins, albumin or plasma protein fraction.
There is overlap between albumin given for volume replacement
and albumin given as a nutritional supplement, andmany patients
with a critical illness have low serum albumin. Where the trial
was of total parenteral nutrition with or without albumin, we
excluded it. We included trials where the albumin was given as
part of volume replacement guided by colloid osmotic pressure or
albumin levels.
The control group received crystalloid (isotonic or hypertonic)
for fluid replacement. We included trials in which both groups
received blood.
We excluded trials of fluids used for other purposes. For exam-
ple, we excluded trials of pre-loading in preparation for elective
surgery, and trials in patients undergoing fluid loading before car-
diopulmonary bypass.
Types of outcome measures
The principal outcome measure was mortality from all causes,
assessed at the end of the follow-up period scheduled for each trial.
Search methods for identification of studies
The searches were not restricted by date, language or publication
status.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group Specialised Register (searched 30
Sept 2008)
• CENTRAL (The Cochrane Library 2008, Issue 3)
• MEDLINE (1966 to September 2008)
• PubMed (searched 30 September, last three months)
• EMBASE (1980 to September 2008)
• ISI Web of Knowledge (1970 to September 2008)
• National Research Register (2006, Issue 4)
• Controlled Trials metaRegister (www.controlled-trials.com)
(searched 30 Sept 2008)
The search strategy can be found in Appendix 1.
Searching other resources
We checked the reference lists of all identified trials and review
articles, and contacted the trialists to identify any studies that may
have been missed.
Data collection and analysis
Selection of studies
We independently examined titles, abstracts, and keywords of ci-
tations from electronic databases for eligibility. We obtained the
full text of all relevant records and independently assessed whether
each met the pre-defined inclusion criteria. We resolved disagree-
ment by discussion.
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Assessment of risk of bias in included studies
We scored allocation concealment as described by Higgins 2008,
assigning ’No’ to poorest quality and ’Yes’ to best quality (the pres-
ence of solutions in identical containers was only taken to mean
adequate concealment if the fluid containers were used sequen-
tially).
• Yes = trials deemed to have taken adequate measures to
conceal allocation (that is, central randomisation; serially
numbered, opaque, sealed envelopes; or other description that
contained elements convincing of concealment).
• Unclear = trials in which the authors either did not report
an allocation concealment approach at all or reported an
approach that did not fall into one of the other categories.
• No = trials in which concealment was inadequate (such as
alternation or reference to case record numbers or to dates of
birth).
We collected but did not score information on blinding and loss
to follow up.
Data synthesis
As a result of comments on the previous version of this review, we
have stratified trials by type of fluid rather than type of original
injury.
We calculated relative risks (RRs) and 95% confidence intervals
(95% CI) for each study using a fixed-effect model. We then in-
spected each comparison visually for evidence of heterogeneity and
performed a Chi2 test. If there was no evidence of heterogeneity
(visually or with a P value < 0.1) the trials were pooled within each
type of fluid, but not combined between type of fluid.
We then excluded trials with allocation concealment judged as
inadequate and repeated the calculations.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We identified 65 trials meeting the inclusion criteria for study
design, participants and interventions. We were able to obtain
mortality data for 56 of these. We have reported details of the
included trials in the ’Characteristics of included studies’ table.
Reasons for exclusion of trials were: the use of a cross-over design,
testing a resuscitation algorithm, giving the control group oral
fluids, the interventionbeingdirected to themaintenance of serum
albumin levels, for haemodilution, for fluid loading and for the
reduction of intracranial pressure (see ’Characteristics of excluded
studies’ table).
Of the 56 trials with data on deaths, the quality of allocation
concealment was adequate in seven trials and unclear in most of
the others.
There were 60 comparisons of colloids and crystalloids (add-on
colloid), nine comparisons of colloid inhypertonic crystalloidwith
isotonic crystalloid, and three comparisons of colloid with hyper-
tonic crystalloid.
Risk of bias in included studies
In general, the design of studies was not well reported. This is
reflected in the number of unclear scores given for allocation con-
cealment. We also collected information on blinding and loss to
follow up. Blinding was not well reported and loss to follow up
was generally small. The characteristics for each trial are listed in
the ’Characteristics of included studies’ table.
Effects of interventions
Colloids compared to crystalloids
Albumin or plasma protein fraction
Twenty-three trials reported data on mortality, including a total
of 7754 patients. The pooled relative risk (RR) was 1.01 (95%
confidence interval (95% CI) 0.92 to 1.10). When we excluded
the trial with poor quality allocation concealment (Lucas 1978),
pooled RR was 1.00 (95% CI 0.91 to 1.09).
Hydroxyethyl starch
Seventeen trials compared hydroxyethyl starch with crystalloids,
including a total of 1172 randomised patients. The pooled RR
was 1.18 (95% CI 0.96 to 1.44).
Modified gelatin
Eleven trials comparedmodified gelatinwith crystalloid, including
a total of 506 randomised patients. The pooled RRwas 0.91 (95%
CI 0.49 to 1.72).
Dextran
Nine trials compared dextran with a crystalloid, including a total
of 834 randomised patients. The pooled RR was 1.24 (95% CI
0.94 to 1.65).
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Colloids in hypertonic crystalloid compared to
isotonic crystalloid
One trial compared albumin and hypertonic saline with isotonic
crystalloid. The RR of death was 0.50 (95% CI 0.06 to 4.33).
Eight trials compared dextran in hypertonic crystalloid with iso-
tonic crystalloid, including 1283 randomised patients. The pooled
RR was 0.88 (95% CI 0.74 to 1.05).
Colloids in isotonic crystalloid compared to
hypertonic crystalloid
Three trials compared colloids in isotonic crystalloid with hyper-
tonic crystalloid. In two of these, where the colloid was either
gelatin or starch, there were no deaths in either group. In the re-
maining trial, with 38 patients, there was a RR of death of 7.00
(0.39 to 126.93) for use of colloid, based on three deaths in the
treatment group and none in the control group.
D I S C U S S I O N
This systematic review synthesises the evidence from RCTs com-
paring colloid and crystalloid fluid resuscitation across a wide vari-
ety of clinical conditions. The review has been updated and exten-
sively revised to take into account the comments made since it was
first published. In particular, several commentators pointed out
that it is inappropriate to combine effect estimates from studies
of different colloids. For example, it was argued that large molec-
ular weight colloids such as hydroxyethyl starch may be better re-
tained in the vascular compartment than albumin and gelatins,
and would therefore be more likely to show a favourable effect
on mortality (Gosling 1998). In response to these concerns, the
review has been stratified by type of colloid. However, the pooled
relative risks fail to show a mortality benefit for resuscitation with
any type of colloid.
There was a trend towards a favourable effect on mortality for col-
loids in hypertonic crystalloid, compared to isotonic crystalloids.
Nevertheless, the results are compatible with the play of chance.
Common to all meta-analyses, this systematic review may have in-
cluded studies whose interventions and patient characteristics are
sufficiently incomparable that the calculation of a summary effect
measure may be questioned. The resuscitation regimen differed
between trials. Some trials randomised participants to an initial
quantity of colloid or crystalloid, and then proceeded with some
form of standard resuscitation for all participants. Other trials re-
suscitated with the allocated fluid to pre-determined end-points,
either resuscitation end-points, or in the case of trauma, until cor-
rective surgery. In addition, the type of colloid or crystalloid, the
concentration, and the protocol to determine the quantity of fluid
varied. Despite these differences, all participants were in need of
volume replacement, and we believe that this variation in the in-
tervention would have an impact on the size of the effect, rather
than on its direction.
As regards the effects of albumin versus crystalloid, most of the
information (as indicated by the weighting in the meta-analysis)
was provided by the SAFE trial (SAFE 2004). The SAFE trial used
central randomisation with a minimisation algorithm to ensure
balance on known potential confounders. Blinding was assured
through the use of specially designedmasking cartons and specially
designed and manufactured administration sets. The trial authors
report that the effectiveness of the blinding was confirmed in a
formal study before the trial was initiated. In brief, this was a well-
conducted, high-quality trial. There were 726 deaths (20.9%) in
the albumin-treated group and 729 deaths (21.1%) in the saline-
treated group (RR of death 0.99; 95% CI 0.91 to 1.09). Although
even this large trial was unable to confirm or refute the possibil-
ity of a modest benefit or harm from albumin, it has provided
some reassurance that any hazard from albumin, if indeed there
is any, is unlikely to be as extreme as was suggested by the results
from the previously published (now here updated) meta-analysis
of much smaller trials. The pooled RR for death with albumin in
this updated meta-analysis is now 1.02 (95% CI 0.93 to 1.11). It
is important to note that the effect estimate from the SAFE trial is
entirely consistent with the results of previous trials of albumin in
hypovolaemia and there is no significant heterogeneity (I2 = 0%,
P = 0.46).
The results of this updated meta-analysis have important policy
implications. There is still no evidence that colloids are superior to
crystalloids as a treatment for intravascular volume resuscitation in
critically ill patients. Importantly, the SAFE trial also provided no
evidence of any other clinical advantages from using albumin. It
also debunked the belief, from pathophysiological inference, that
very large volumes of crystalloid must be administered to reach
the same resuscitation end-points as can be achieved using much
smaller volumes of colloid. In the SAFE trial, the ratio of albumin
administered to saline administered was approximately 1:1.4. Col-
loids, in particular albumin, are considerably more expensive than
crystalloids, and albumin is a blood product and so carries at least
a theoretical infectious disease risk. The economic opportunity
cost of ongoing colloid use, particularly albumin use, is likely to
be considerable and for this reason its ongoing use in this context
is unjustified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from RCTs that resuscitation with colloids,
instead of crystalloids, reduces the risk of death in patients with
trauma, burns or following surgery. As colloids are not associated
with an improvement in survival, and further, colloids are consid-
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erably more expensive than crystalloids, it is hard to see how their
continued use outside the context of RCTs in subsets of patients
of particular concern, can be justified.
Implications for research
Future trials may need to concentrate on specific subgroups of
patients to identify people who may benefit from colloids rather
than crystalloids.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boldt 1986
Methods Randomised controlled trial, using sealed opaque envelopes.
Information on allocation concealment was obtained on contact with the authors.
Blinding and loss to follow up not mentioned.
Participants 55 patients undergoing elective aorta-coronary bypass surgery.
Exclusion criteria were ejection fraction < 50% and LVEDP > 15 mmHg
Interventions 1. 300ml 20% human albumin solution (n = 15).
2. 500ml 3% hydroxyethyl starch (n = 13).
3. 500ml 3.5% gelatin (n = 14).
4. No colloid (n = 13).
Outcomes Haemodynamic variables were measured.
Deaths not reported.
Notes Follow up until discharge from intensive care.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Boldt 1993
Methods Randomised controlled trial.
Allocation concealment by sealed opaque envelopes (information from author).
Blinding and loss to follow up not mentioned.
Participants 75males undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary wedge pressure
of less than 5 mmHg after induction of anaesthesia
Interventions 1. 5% albumin (n = 15).
2. 6% HES, mean molecular weight 450,000 (n = 15).
3. 6% HES, mean molecular weight 200,000 (n = 15).
4. 3.5% gelatin (n = 15).
5. No colloid (n = 15).
Fluid used through operation and on intensive care post-op.
Outcomes Deaths not reported, author confirmed there were no deaths.
Notes Follow up to 1 day.
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Boldt 1993 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Boldt 2001
Methods Randomised controlled trial, using a closed-envelope system.
Participants 100 patients undergoing major abdominal surgery.
Interventions 1. Ringer’s lactate (n = 25).
2. 6% HES, mean molecular weight 200kDa, degree of substitution 0.5 (n = 25).
3. 6% HES, mean molecular weight 130kDa, degree of substitution 0.4 (n = 25).
4. 4% modified fluid gelatin, molecular weight 35kDA (n = 25).
Outcomes Deaths.
Orthostatic problems.
Haemodynamics and laboratory data.
Fluid input and output.
Costs.
Notes Follow-up period unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Boutros 1979
Methods Randomised controlled trial (“randomly divided”).
Method of allocation concealment not described.
Blinding not mentioned.
No loss to follow up.
Participants 24 people undergoing major operative procedures on the abdominal aorta
Interventions 1. Albumin in 5% dextrose (n = 7).
2. 5% dextrose and Ringer’s lactate (n = 8).
3. 5% dextrose in 0.45% saline (n = 9).
Allocated fluids were used on admission to ICU, following surgery, guided by PAWP. Whole blood also
given if clinically needed
Outcomes Deaths reported.
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Boutros 1979 (Continued)
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Bowser-Wallace 1986
Methods Quasi-randomised controlled trial (allocation by alternation).
Blinding not mentioned.
No loss to follow up.
Participants Admitted for burns of 30% or more.
Age range 5 months to 21 years.
Excluded if already given more than half calculated daily requirement before reaching hospital
Interventions 1. 2ml/kg/%burn Ringer’s lactate over 24 hrs, then 0.5ml plasmanate/kg/%burn over 24 hrs plus 5%
dextrose (n = 19).
2. 2ml/kg/%burn hypertonic lactated saline over 24 hrs, then 0.6ml/kg/%burn hypertonic lactated
saline over 24 hrs plus oral Haldane’s solution (n = 19).
IV fluids stopped at 48 hrs (n = 19).
Outcomes Deaths reported.
Fluid and electrolytes given, weight, haematocrit.
Notes Follow up to 5 days.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate.
Brunkhorst 2008
Methods Multicenter, randomised control study. Blinding not mentioned. Use of a two-by-two factorial, open label
study design
Participants Critically ill patients with severe sepsis or septic shock of at least 18 years of age. Excluded if onset of
symptoms commenced more than 24 hours before admission to the ICU, if the symptoms commenced
more than 12 hours after onset in the ICU or if patient had received more than 1000 ml of HES in the
24 hours before randomisation
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Brunkhorst 2008 (Continued)
Interventions 1. 10% Pentastarch/HES (200/0.5) (n = 262)
2. Modified Ringer’s Lactate (n = 275)
Outcomes Deaths reported at 28 and 90 days. 90 day mortality rate was cited as it marked the end of the follow-up
period
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Chavez-Negrete 1991
Methods Randomised controlled trial (allocation by “random numbers”).
Blinding not mentioned.
No loss to follow up.
Participants Adults admitted to an emergency room with acute gastrointestinal haemorrhage, systolic blood pressure
90 mmHg or less for up to 1 hr and normal electrocardiograph.
Excluded if pregnant or had renal, cardiac or neurological disease
Interventions 1. Initial infusion of 250ml 7.5% saline/6% Dextran 60 given IV (16 patients) or intraosseous (n =
10).
2. Initial IV infusion of 250ml Ringer’s lactate (n = 23).
Resuscitation continued with red cells, 0.9% saline and Dextran 40 according to clinical judgement
Outcomes Death.
Haemodynamic variables.
Notes Follow up to 24 hours.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear.
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Cifra 2003
Methods Quasi-randomised controlled trial (allocation by alternation).
Allocation concealment not reported.
Blinding not reported.
No loss to follow up.
Participants 27 children with dengue shock syndrome.
Exclusion criteria included: Other severe infection, protein-deficient abnormalities, bleeding diathesis,
patients who have been given multiple plasma substitutes
Interventions 1. 6% Haes-Steril (n = 11).
2. Ringer’s Lactate (n = 16).
One patient from group 1 and three from group 2 were excluded because they needed inotropic support
and multiple plasma substitute
Outcomes Duration of control of shock.
Recurrence of shock.
Length of ICU stay.
Death not reported as an outcome but they reported that 4 patients died
Notes Length of follow up not reported but all outcomes were in-hospital
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not used
Dawidson 1991
Methods Randomised controlled trial (allocation by drawing a card from a deck).
Blinding not mentioned.
No loss to follow up.
Participants Adults undergoing elective abdominal aortic surgery.
No exclusions mentioned.
Interventions 1. 3% Dextran 70 in Ringer’s lactate (n = 10).
2. IV Ringer’s lactate (n = 10).
Fluid used during and for 24 hrs after operation, guided by haemodynamic variables
Outcomes Death.
Volume transfused, weight change, haemodynamic variables.
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
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Dawidson 1991 (Continued)
Allocation concealment? No Inadequate
Dehne 2001
Methods Randomised controlled trial; allocation by sealed envelope assignment
Participants 60 male patients (of American Society of Anesthesiologists physical status 1 or 2) scheduled for middle
ear surgery
Interventions 1. Lactated Ringer’s solution (n = 15).
2. 6% HES: molecular weight 200kD, degree of substitution 0.5 (n = 15).
3. 6% HES: molecular weight 200kD, degree of substitution 0.60-0.66 (n = 15).
4. 6% HES: molecular weight 450kD, degree of substitution 0.7 (n = 15).
Outcomes Deaths not stated but ’all’ patients discharged 10-14 days after surgery; therefore no deaths.
Central venous pressure.
Urine output.
Blood osmolality.
Urine osmolality.
Notes Follow up two days.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Eleftheriadis 1995
Methods Patients “randomizedly distributed”.
Blinding not mentioned.
Unable to assess loss to follow up.
Participants Participants were undergoing coronary artery bypass surgery.
Interventions 1. 6% hydroxyethyl starch.
2. 3.5% gelatin.
3. Ringer’s lactate.
Allocated fluid was used in the post-operative period only guided by mean arterial pressure
Outcomes Deaths were not reported.
Haemodynamic variables.
Notes Follow up period unspecified.
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Eleftheriadis 1995 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Ernest 1999
Methods Randomised controlled trial, allocation concealment not described.
No blinding.
No loss to follow up mentioned.
Participants Patients with a clinical diagnosis of sepsis.
Interventions 1. 5% albumin (n = 9).
2. 0.9% saline (n = 9).
Volume of infusion guided by PAWP.
Outcomes Haemodynamic variables and volume measurements.
Deaths not reported.
Notes Follow up to immediately after infusion.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Evans 1996
Methods Quasi-randomised trial (allocation by day of the week).
Blinding not mentioned.
No loss to follow up.
Participants Aged 16 ormore, admitted with trauma to an emergency centre within 2 hours after injury, only crystalloid
as a pre-hospital infusion.
Excluded if had underlying illness likely to affect clotting
Interventions 1. IV haemaccel (n = 11).
2. IV Ringer’s lactate (n = 14).
Fluid was used until vital signs were stable.
Outcomes Deaths from author.
Clotting variables.
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Evans 1996 (Continued)
Notes Follow up period unspecified.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate
Evans 2003
Methods Randomised controlled trial.
Allocation concealment not reported.
Blinding methods not reported.
Loss to follow up not reported.
Participants 55 patients undergoing primary unilateral total hip replacement.
Exclusion criteria were pre-existing defect in platelet function or on aspirin that could not be stopped for
2 weeks prior to the operation
Interventions 1. 4.5% Albumin (n = 13).
2. Gelofusine (n = 14).
3. Haemaccel (n = 14).
4. 0.9% Saline (n = 14).
Outcomes Haemostatic parameters.
Death not reported.
Notes Length of follow up not reported but all outcomes were in-hospital
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Fries 2004
Methods Randomised controlled trial. (Patients “randomly” received crystalloid or colloids.)
Method of allocation concealment not reported.
Blinding not reported.
Loss to follow up not reported.
Participants 60 patients undergoing knee replacement surgery.
Exclusion criteria were contraindication for regional anaesthesia, known allergies or haemostatic disorders
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Fries 2004 (Continued)
Interventions 1. HES (n = 20).
2. Modified gelatin (n = 20).
3. Ringer’s solution (n = 20).
Groups 1 and 2 also received a basis of Ringer’s solution infusion
Outcomes Coagulation parameters.
Death not reported.
Notes Length of follow up not reported but all outcomes were in-hospital measures
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Gallagher 1985
Methods Randomised controlled trial. Method of allocation concealment not described. Author contacted - allo-
cation concealment by computerised system - patient details were entered before treatment assignment
was revealed.
Blinding not mentioned.
No loss to follow up.
Participants Patients after coronary artery bypass graft surgery.
Exclusions: patients with significant left main coronary artery stenosis, poor left ventricular function or
poor pulmonary function
Interventions 1. IV 5% albumin (n = 5).
2. IV 6% hydroxyethyl starch (n = 5).
3. IV Ringer’s lactate (n = 5).
Fluid used from admission to intensive care post op, guided by PAWP. RBC given if needed.
Five patients received 5% albumin. Five patients received lactated Ringer’s
Outcomes Deaths were not reported. Author contacted and confirmed that there were no deaths in any group.
Haemodynamic data.
Notes Follow up to 1 day.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
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Goodwin 1983
Methods Randomised controlled trial - assigned by “random numbers table”.
Method of allocation concealment unclear.
Blinding not mentioned.
No loss to follow up.
Participants 79 previously healthy young adults admitted with burns.
No exclusion criteria reported.
Interventions 1. 2.5% albumin in Ringer’s lactate (n = 40).
2. Ringer’s lactate (n = 39).
Fluids on day 1 guided by haemodynamic variable. On day 2, given at 0.3-0.5ml/kg/%burn, then 5%
dextrose
Outcomes Deaths reported.
Lung water in some.
Infections.
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Grundmann 1982
Methods Randomised controlled trial.
Method of allocation concealment unclear.
Blinding not mentioned.
No loss to follow up.
Participants 20 people undergoing partial gastrectomy.
The average age was 50 years (range 19-84).
No exclusion criteria reported.
Interventions 1. Colloid group received human albumin solution (n = 14).
2. Details of crystalloid were not reported (n = 6).
Allocated fluid was continued for 4 days after operation.
Outcomes Deaths reported.
Volumes of fluid given.
Haemodynamic variables.
Notes Follow up to discharge from hospital.
Risk of bias
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Grundmann 1982 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Guo 2003
Methods Randomised controlled trial.
Allocation concealment not reported.
Blinding not reported.
No loss to follow up reported.
Participants 42 patients undergoing elective cytoreductive surgery for ovarian cancer.
Exclusion criteria included: preoperative anaemia, allergic response toHES or perioperative administration
of cardiovascular agents.
2 patients randomised but excluded because of use of cardiovascular agents
Interventions 1. Ringer’s Lactate (n = 20).
2. 6% HES (n = 20).
Outcomes Splanchnic perfusion.
Death not reported but in results authors mentioned that “all patients were discharged.”
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Hall 1978
Methods Quasi-randomised controlled trial (participants were stratified by age, extent of burn and aetiology, and
then allocated by alternation).
Blinding not mentioned.
No loss to follow up.
Participants Burns covering more than 10% of the body surface (for children), and more than 15% of the body surface
(for adults).
No exclusions mentioned.
Interventions 1. 120ml/%burn IV 6% Dextran 70 in 0.9% saline over 48 hrs plus oral water or IV 5% dextrose for
’metabolic requirements’ (n = 86).
2. 4ml/kg/%burn IV Ringer’s lactate over 24 hrs, then 10% of initial body weight of fluid over 24 hrs
plus oral water (n = 86).
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Hall 1978 (Continued)
Outcomes Death.
Fluid given, haemodynamic variables.
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate
Hartmann 1993
Methods Randomised controlled trial (method of allocation unclear).
Blinding not mentioned.
No loss to follow up.
Participants Adults undergoing major abdominal surgery.
Exclusions: cardiorespiratory dysfunction, uraemia, diabetes, taking steroids, anticoagulants or diuretics
Interventions 1. IV Dextran 70 in saline (concentration not given) with 2.5% dextrose (n = 15).
2. IV saline (concentration not given) with 2.5% dextrose (n = 14).
Both groups given red cells, plasma, Dextran 70 and crystalloids during the operation as decided by the
clinician. Post-operative fluids according to the trial group guided by tissue oxygen tension to the end of
resuscitation
Outcomes Death not reported.
Fluid given, haemodynamic variables.
Notes Follow up to 7 days.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Jelenko 1978
Methods Randomised controlled trial, method of allocation concealment unclear.
Blinding not mentioned.
No loss to follow up.
Participants 19 people with burns covering more than 20% of body surface.
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Jelenko 1978 (Continued)
Interventions 1. 12.5% albumin in hypertonic saline (240MeQ Na+, 120 MeQ chloride, 120 MeQ lactate), (n = 7).
2. Hypertonic saline (240MeQ Na+, 120 MeQ chloride, 120 MeQ lactate). (n = 5).
3. Ringer’s lactate (n = 7).
Allocated fluid was used, guided by haemodynamic variables, to the end of resuscitation
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow up to end of resuscitation.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Karanko 1987
Methods Randomised controlled trial. Description of allocation procedure unclear.
Blinding not mentioned.
No loss to follow up.
Participants 32 adult men scheduled for coronary artery bypass surgery.
Exclusions: left ventricular ejection fraction under 40%, abnormal lung function
Interventions 1. Colloid group received 6% dextran 70 (n = 14).
2. Ringer’s lactate (n = 18).
Allocated fluid was used to the end of resuscitation.
Outcomes Deaths reported.
Haemodynamic variables.
Lung water.
Notes Follow up 2 weeks.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Lang 2001
Methods Randomised controlled trial, using a closed-envelope system.
Participants 42 patients scheduled for elective major abdominal surgery.
Interventions 1. Lactated Ringer’s (n = 21).
2. 6% HES, molecular weight 139kD, degree of substitution 0.4 (n = 21).
Outcomes Deaths.
Haemodynamics and laboratory data.
Tissue oxygenation.
Volume input and output.
Notes Follow up period unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
Lang 2003
Methods Randomised controlled trial.
Allocation concealment not clearly reported (“Closed envelope system”).
Blinding method not reported (“...treatment in the ICU was performed by physicians who were blinded
to the study”)
Participants 36 patients undergoing elective major abdominal surgery.
Exclusion criteria included:myocardial failure, renal insufficiency, severe pulmonary disease, liver dys-
function, diabetes mellitus, steroid therapy, pre-existing viral or bacterial infection and known allergic
reactions to starch preparations
Interventions 1. 6% HES (n = 18).
2. Ringer’s Lactate (n = 18).
Additional crystalloid solutions were supplied to equalize insensible fluid loss or as a solvent for drugs in
group 1
Outcomes Pro- and anti-inflammatory cytokines.
All patients survived.
Notes Length of follow up not reported but all outcomes were in-hospital measures
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Ley 1990
Methods Randomised controlled trial.
Method of allocation concealment unclear.
Assessment of chest x-ray blinded.
No loss to follow up.
Participants 21 people undergoing coronary artery bypass grafting or valve surgery
Interventions 1. 6% hetastarch up to 1.5L then 5% plasma protein fraction (n = 11).
2. 0.9% saline (n = 10).
Allocated fluid was used for post-operative fluid resuscitation
Outcomes Deaths were not reported.
Pulmonary and peripheral oedema.
Haemodynamic variables.
Notes Follow up to discharge.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Lowe 1977
Methods Randomised controlled trial, allocation by sealed envelopes.
Blinding not mentioned.
No loss to follow up.
Participants Participants with serious trauma.
Interventions 1. 25% albumin in Ringer’s lactate (n = 77).
2. Ringer’s lactate (n = 94).
Allocated fluid was used throughout the pre- and intra-operative period
Outcomes Deaths reported.
Notes Follow up to 5 days post-operatively. Data on the 30 participants with chest injuries who were left out of
the Lowe 1977 report, but included in Moss 1981, have been included in the meta-analysis
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
27Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lucas 1978
Methods Randomised controlled trial.
Randomisation was based on the last digit of each patient’s case number
Participants 52 seriously injured patients.
Interventions 1. Standard resuscitation regimen (’balanced electrolyte’, blood, fresh frozen plasma) plus salt poor
albumin, maximum 150g during surgery and 150g per day for the next 5 days (n = 27).
2. Standard resuscitation regimen as above (n = 25).
Outcomes Deaths reported in some patients.
Notes In the final report of 94 randomised patients deaths were not reported. However, in this preliminary report
of 52 injured patients deaths were reported
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate
Maitland 2005
Methods Randomised controlled trial.
Open label.
Random allocation was assigned by the use of sealed cards.
No loss to follow up.
Participants 159 children with severe malaria and metabolic acidosis.
Exclusion criteria included pulmonary oedema, oedematous malnutrition or papilledema
Interventions Severe acidosis
1. 4.5% Albumin (n = 23).
2. 0.9% Saline (n = 26).
Moderate acidosis
1. 4.5% Albumin (n = 33).
2. 0.9% Saline (n = 35).
3. Control (n = 33).
Outcomes Reduction in base deficit.
Neurological sequelae.
Death reported.
Notes Length of follow up not reported but all outcomes were in-hospital measures
Risk of bias
Item Authors’ judgement Description
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Maitland 2005 (Continued)
Allocation concealment? Unclear Unclear
Mattox 1991
Methods Quasi-randomised, allocation by alternation.
Double-blind.
2 patients excluded from the analysis as code of fluid lost.
Participants Participants were pre-hospital trauma victims attended to by emergency personnel within an hour of
injury, who had systolic blood pressure of 90mmHg or less and were 16 years or older. 72% of participants
had sustained penetrating trauma
Interventions 1. 250 mL Dextran-70 in 7.5% NaCl (n = 211).
2. 250 mL Ringer’s lactate, saline or plasmalyte (n = 211).
Allocated fluid was for initial pre-hospital resuscitation only
Outcomes Deaths reported.
Notes Follow up to hospital discharge or transfer.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate
Mazher 1998
Methods Patients ’randomized’.
Blinding of care givers by use of pharmacy prepared solutions.
No loss to follow up.
Participants Patients undergoing elective coronary artery surgery.
Exclusions: age over 75, ejection fraction under 35%, creatinine over 135umol/L, ACE inhibitors
Interventions 1. 5mL/kg polygeline (n = 10).
2. 5mL/kg 7.2% saline (n = 10).
Allocated fluid given post-op over one hour. All patients subsequently receive polygeline and red blood
cells
Outcomes Haemodynamic variables.
Death.
Notes Follow up to discharge from intensive care.
Risk of bias
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Mazher 1998 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
McNulty 1993
Methods Randomised controlled trial. Method of allocation concealment not described.
Blinding not mentioned.
No loss to follow up.
Participants Patients following elective cardiopulmonary bypass.
Interventions 1. 5% albumin and cell-saved blood (n = 14).
2. Plasmalyte and cell-saved blood (n = 14).
Allocated fluid used as part of fluid volume replacement.
Outcomes Deaths not reported.
Study was designed to look at the effect of protein infusion on the accuracy of a haematocrit measuring
device
Notes Length of follow up unspecified.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Metildi 1984
Methods Randomised controlled trial.
Blinding not mentioned.
No loss to follow up.
Participants Participants were admissions to an intensive care and a trauma unit with adult respiratory distress syndrome
and established pulmonary failure. Included both trauma and non-trauma patients
Interventions 1. 5% salt-poor albumin (n = 20).
2. Ringer’s lactate (n = 26).
Allocated fluid was used throughout resuscitation, and if an operation was required the allocated fluid was
used for volume replacement before and during the operation
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow up to discharge.
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Metildi 1984 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Modig 1983
Methods Quasi-randomised controlled trial, allocation by admission date.
Blinding not mentioned.
No loss to follow up.
Participants Participants were trauma admissions to an emergency department with a systolic blood pressure of less
than 70mmHg. Age range was 20-58 years
Interventions 1. Dextran-70 in Ringer’s lactate (n = 12).
2. Ringer’s lactate (n = 11).
Allocated fluids were given as the initial resuscitation fluid on admission to the emergency department,
and continued as needed until after the 6th day when major reconstructive surgery was undertaken
Outcomes Deaths reported.
Development of respiratory distress syndrome.
Notes Follow up to definitive reconstructive surgery.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate
Moretti 2003
Methods Randomised controlled trial.
Allocation concealment method not clearly reported (“Patients randomized...by using a closed-envelope
technique”).
Blinding method not clearly reported (“Researchers were unaware of the patient’s randomization”).
No loss to follow up.
Participants 90 adult patients undergoing major elective general, gynaecological, orthopedic or urologic surgery with
an anticipated blood loss > 500 ml.
Exclusion criteria included age < 16 years, coagulopathy, renal or hepatic dysfunction and congestive heart
failure
Interventions 1. Hetastarch-Normal Saline (n = 30).
2. Hetastarch-Balanced Salt (n = 30).
3. Ringer’s Lactate (n = 30).
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Moretti 2003 (Continued)
Outcomes Postoperative nausea and vomiting.
Death not reported.
Notes Follow up to discharge.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Nagy 1993
Methods Randomised controlled trial, contact with author showed it was an open label study.
Blinding not mentioned.
No loss to follow up.
Participants Participants were adult admissions to a trauma unit, with measurable systolic blood pressure less than 90
mmHg
Interventions 1. Pentastarch in 0.9% NaCl (n = 21).
2. Ringer’s lactate (n = 20).
Allocated fluid was used throughout resuscitation with the exception that colloid patients received a
maximum 4L of pentastarch, after which Ringer’s lactate was given
Outcomes Deaths were not reported.
Haemodynamic variables.
Notes Follow up to discharge.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Inadequate
Ngo 2001
Methods Randomised controlled trial, opaque envelopes containing only treatment pack number
Participants 230 children with dengue shock syndrome.
Interventions 1. Dextran 70 (n = 55).
2. 3% gelatin (n = 56).
3. Lactated Ringer’s (n = 55).
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Ngo 2001 (Continued)
4. ’Normal’ saline (n = 56).
Outcomes Initial pulse recovery time.
Occurrence of timing and subsequent episodes of shock.
Fall in haematocrit.
Volume of fluid administered till recovery.
Complications.
And noted that there were no deaths in any group
Notes Follow up period unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
Nielsen 1985
Methods Randomised controlled trial.
Method of allocation concealment not described.
Blinding not mentioned.
No loss to follow up.
Participants 26 patients admitted for reconstructive surgery of the abdominal aorta
Interventions 1. Whole blood, crystalloid plus 80g albumin on the day of the operation, and 20g per day for the
next 3 days. Albumin given as 100mL 20% human albumin solution (n = 13).
2. Whole blood and crystalloid, type not specified (n = 13).
Outcomes Deaths not reported.
Author when contacted confirmed that there were no deaths in either group
Notes Length of follow up 4 days.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Pockaj 1994
Methods Randomised controlled trial, allocation concealment unclear.
Blinding not mentioned.
Loss to follow up 18/54 in colloid group, 13/53 in saline group
Participants Participants required fluid resuscitation as a result of vascular leak syndrome associated with Interleukin-
2 therapy for metastatic cancer
Interventions 1. 250 mL boluses of 5% albumin in saline (n = 36 reported).
2. 250 mL boluses of 0.9% normal saline (n = 40 reported).
Boluses guided by haemodynamic variables. Both groups also received 0.45% saline with 10mmol/L KCl
Outcomes Deaths.
Toxic effects of chemotherapy.
Haemodynamic variables.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Prien 1990
Methods Randomised controlled trial.
Blinding not mentioned.
No loss to follow up.
Participants Participants were undergoing modified Whipple’s operation.
Interventions 1. 10% hydroxyethyl starch in 0.9% saline plus plasma protein fraction if requirements > 20mL/kg (n
= 6).
2. 20% human albumin solution (n = 6).
3. Ringer’s lactate.
Allocated fluid was administered intra-operatively only.
Outcomes Deaths.
Intestinal oedema formation.
Notes Follow up period was unspecified.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Rackow 1983
Methods Randomised controlled trial, allocation concealment unclear.
Blinding not mentioned.
No loss to follow up.
Participants Participants were aged 54 to 97, and had any one of the following pre-determined indicators of shock:
systolic blood pressure of 90 mmHg or less, a cardiac index of less than 2.2 L./min.m2, a serum arterial
lactate greater than 18mg/dl and WP less than 15mmHg
Interventions 1. 6% hydroxyethyl starch (n = 9).
2. 5% albumin (n = 9).
3. 0.9% saline (n = 8).
Allocated fluid was given as needed until the end of resuscitation
Outcomes Deaths reported.
Fluid balance.
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Rocha e Silva 1994
Methods Randomised controlled trial.
Participants Participants were admissions to the emergency room, with a systolic blood pressure of 90 mmHg or less
and were 16 years of age or older
Interventions Colloid group received 6% dextran-70 in 7.5%NaCl; crystalloid group receivedRinger’s lactate. Allocated
fluid was used for the first intravenous infusion only
Outcomes Death was the main outcome measure, but the data are unpublished
Notes Follow up to 30 days. By April 1994, 125 patients had been entered into the study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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SAFE 2004
Methods Randomised controlled trial. Randomisation by minimisation algorithm accessed through secure website
Participants Patients aged 18 years and above admitted to closed multidisciplinary intensive care units in 16 tertiary
hospitals in Australia over 19-month period
Interventions 1. 4% albumin (Albumex, CSL) (n = 3499).
2. Normal saline (n = 3501).
Outcomes Death.
Patients with new single or multiple-organ failure.
Mean number of days: in ICU, in hospital, on mechanical ventilation, on renal replacement therapy
Notes Follow up to 28 days.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
Shah 1977
Methods Randomised controlled trial. Allocation by sealed envelope.
Blinding not mentioned.
No loss to follow up.
Participants Patients with severe, multiple trauma and a systolic blood pressure of less than 90mmHg. All patients
were adults and both sexes were included
Interventions 1. 5% salt-poor albumin in Ringer’s lactate (n = 9).
2. Ringer’s lactate (n = 11).
Volume infused guided by physiological parameters.
Outcomes Death reported.
Haemodynamic variables.
Notes Length of follow up not stated.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Shires 1983
Methods Patients ’assigned randomly’.
Blinding not mentioned.
No loss to follow up.
Participants People undergoing aortic reconstruction surgery.
No exclusion criteria mentioned.
Interventions 1. Plasmanate (n = 9).
2. Ringer’s lactate (n = 9).
Allocated fluid used guided by haemodynamic variables until the first postoperative morning. All patients
then received 0.45% saline
Outcomes Lung water.
Haemodynamic variables.
Death.
Notes Follow up to two days post-op.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Sirieix 1999
Methods Patients “randomly assigned”. Blinding not described.
Two patients excluded after randomisation due to arrhythmias on giving the fluid (both in hypertonic
saline group)
Participants Patients undergoing mitral valve repair.
Exclusions: LVEF < 0.4, systolic PAP > 50mmHg, coagulation disorders, creatinine >150mmoL/L, elec-
trolyte imbalance, diabetes, previous atrial fibrillation lasting > 1 year
Interventions 1. 250mL 7.2% hypertonic saline, 6%HES (n = 8).
2. 250mL 7.2% hypertonic saline (n = 10).
3. 250mL 6% HES (n = 8).
Fluid given over 15mins, 1 hour after admission to post-op intensive care
Outcomes Haemodynamic variables.
Deaths reported.
Side effects (2 had severe hypotension in group 2 and 1 in group 1; arrhythmias in 1 patient in group 1,
3 in group 2 and 1 in group 3)
Notes Follow up to discharge from hospital (all within 10 days).
Risk of bias
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Sirieix 1999 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Skillman 1975
Methods Randomised controlled trial, allocation concealment unclear.
Blinding not mentioned.
No loss to follow up.
Participants Participants were undergoing elective abdominal reconstructive surgery
Interventions 1. 25% salt-poor albumin 1g/kg and 5% albumin 1L (n = 7).
2. Ringer’s lactate.
Allocated fluid was given intra-operatively. All patients received crystalloids only for pre-loading before
surgery
Outcomes Deaths were not reported.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Tollofsrud 1995
Methods Randomised controlled trial, allocation by sealed envelopes.
Blinding not mentioned.
No loss to follow up.
Participants Participants were adult patients in need of volume replacement during and after coronary artery bypass
surgery
Interventions 1. Haemaccel (n = 10).
2. Dextran 70 (n = 10).
3. Albumin 40 (n = 10).
4. Ringer’s lactate (n = 10).
Allocated fluid was used throughout resuscitation.
Outcomes Deaths reported.
Fluid balance.
Notes Follow up to 48 hours.
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Tollofsrud 1995 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Tollofsrud 1998
Methods Randomised controlled trial, allocation by sealed envelope. Described as double blind, no loss to follow
up mentioned
Participants Patients with three vessel coronary artery disease undergoing elective coronary artery surgery. Exclusions:
LVEF < 0.4, ventricular aneurysm, significant arrhythmia, diabetes, renal failure, lung disease
Interventions 1. 4mL/kg of 75mg/mL hypertonic saline in dextran 70 60mg/mL over 30 mins (n = 10).
2. Same volume and rate of isotonic saline (n = 10).
Fluid given just after surgery while still in operating theatre. Ringer’s lactate for additional fluid
Outcomes Fluid balance.
Haemodynamic variables.
Deaths not reported.
Notes Follow up to 48 hours.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Upadhyay 2004
Methods Open label randomised trial.
Allocation by sealed envelope.
No loss to follow up mentioned.
Participants 60 patients with septic shock aged 1 month to 12 years.
Exclusion criteria: age less than one month, multiorgan failure and immunodeficiency states
Interventions 1. Normal saline (n = 31).
2. Polymer from degraded gelatin in saline (gelatin) (n = 29).
Outcomes Haemodynamic data.
Death reported.
Notes Length of follow up not reported but all outcomes were in-hospital measures
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Upadhyay 2004 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Vassar 1990
Methods Randomised controlled trial, allocation concealment unclear.
Double blind study (solutions prepared in identical containers).
No loss to follow up.
Participants Participants were emergency department admissions with trauma and a systolic blood pressure below
80mmHg and were 18 years or older.
Pregnant women and people with preexisting cardiac, hepatic or renal disease were excluded
Interventions 1. 6% dextran 70 in 7.5% saline (n = 23).
2. Ringer’s lactate (n = 24).
Allocated fluids were given as the initial resuscitation in the emergency department. Additional isotonic
crystalloids (Ringer’s lactate) were given as needed
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow up to hospital discharge.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Vassar 1991
Methods Randomised controlled trial, allocation by randomised sequence of coded containers.
Double blind study.
No loss to follow up.
Participants Participants were pre-hospital trauma cases undergoing helicopter transport to an emergency centre, with
a systolic blood pressure of 100mmHg or less and were 18 years or older.
Exclusions: preexisting cardiac renal, hepatic or neurological disease. Peripheral oedema
Interventions 1. 4.2% dextran 70 in 7.5% saline or 6% dextran 70 in 7.5% saline (n = 83).
2. Ringer’s lactate (n = 83).
Fluids were given as the initial resuscitation fluid in the pre-hospital setting. Supplemental isotonic fluids
were given at the discretion of the flight nurses
40Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vassar 1991 (Continued)
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow up to discharge. Allocation was to 4.2% dextran-70; to 6% dextran-70; or to crystalloid; for the
calculation of the summary effect measure, the two dextran groups are combined
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
Vassar 1993a
Methods Randomised controlled blind trial, allocation concealed by random sequence of identical containers.
Double blind study.
36 people excluded post randomisation as deemed not to have met eligibility criteria.
No loss to follow up.
Participants Participants, who were undergoing ambulance transport to an emergency centre, had systolic blood
pressure 90 mmHg or less, and were 18 years or older.
Exclusions: asystolic, undergoing CPR, lack sinus complex on ECG, more than 2 hours after trauma,
pregnant, preexisting seizures, bleeding disorder, hepatic, cardiac or renal disease
Interventions 1. 6% dextran 70 in 7.5% saline (n = 89).
2. 7.5% saline (n = 85).
3. 0.9% saline (n = 84).
Participants received 250mL of the allocated fluid in the pre-hospital setting. Additional isotonic crystal-
loids were given as needed
Outcomes Deaths reported.
Haemodynamic variables.
Trauma scores.
Notes Follow up was to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
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Vassar 1993b
Methods Randomised controlled trial, allocation concealed by sequential use of coded identical containers.
Double blind study.
39/233 patients excluded as deemed not to meet eligibility criteria, unclear from which groups
Participants Participants were pre-hospital trauma cases undergoing helicopter transport to an emergency centre, had
a systolic blood pressure of 100mmHg or less and were 18 years or older.
Exclusions: asystolic, undergoing CPR, lack sinus complex on ECG, more than 2 hours after trauma,
pregnant, preexisting seizures, bleeding disorder, hepatic, cardiac or renal disease
Interventions 1. 12% dextran 70 in 7.5% saline (n = 49).
2. 6% dextran 70 in 7.5% saline (n = 50).
3. 7.5% saline (n = 50).
4. Ringer’s lactate (n = 45).
Participants received 250mL of the allocated fluid in the pre-hospital setting. Additional isotonic crystal-
loids were given as needed
Outcomes Deaths reported.
Haemodynamic variables.
Trauma scores and neurological outcome scores.
Notes Follow up to hospital discharge.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
Verheij 2006
Methods Randomised controlled trial.
Allocation concealment by “the sealed envelope method”.
Blinding method not reported.
No loss to follow up.
Participants 67 patients with presumed hypovolemia after cardiac and major vascular surgery.
Exclusion criteria; age > 79 years and known anaphylactoid reaction to colloids
Interventions 1. Saline (n = 16).
2. Gelatin (n = 16).
3. HES (n = 16).
4. Albumin (n = 16).
Outcomes Haemodynamic data.
Death not reported.
Notes Length of follow up not reported but all outcomes were in-hospital measures
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Verheij 2006 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Virgilio 1979
Methods Allocation “by random number”.
Blinding not mentioned.
No loss to follow up.
Participants Participants were undergoing abdominal aortic surgery.
Interventions 1. 5% albumin (n = 15).
2. Ringer’s lactate (n = 14).
Allocated fluid was used during operation for maintenance of pre-defined physiological parameters, and
the resuscitation was continued with the allocated fluid until the day following the operation. This was
followed by 5% dextrose in half-normal saline, with potassium chloride as needed
Outcomes Deaths reported.
Notes Follow up two and a half weeks.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Wahba 1996
Methods Patients “randomly allocated”.
Blinding not mentioned.
Two patients excluded as they required reoperation for bleeding
Participants 22 adult patients in need of volume replacement following coronary artery bypass surgery.
Exclusions: abnormal left ventricular function, platelet active medication or heparin
Interventions 1. Haemaccel (n = 10).
2. Ringer’s lactate (n = 10).
Allocated fluid was used from the time of admission to intensive care following operation, to the end of
resuscitation
Outcomes Deaths reported.
Pulmonary oedema.
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Wahba 1996 (Continued)
Notes Follow up to discharge.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Wills 2005
Methods Randomised controlled study.
Allocation concealed by specially prepared cardboard containers.
Method of blinding not mentioned.
No loss to follow up.
Participants 512 children with Dengue shock syndrome aged 2 to 15 years.
Interventions Children with immoderately severe shock were randomised to the three interventions:
1. Ringer’s lactate (n = 128).
2. 6 percent dextran 70 (n = 126).
3. 6 percent hydroxyethyl starch 200/0.5 (n = 129).
Children with severe shock were randomized only to either of the two colloids interventions:
1. 6 percent dextran 70 (n = 67).
2. 6 percent hydroxyethyl starch 200/0.5 (n = 62).
Outcomes Requirement for supplemental intervention with rescue colloid.
Time taken to achieve initial cardiovascular stability.
Time taken to achieve sustained cardiovascular stability.
Volume required.
Change in the Hematocrit.
Days in hospital.
One death reported but not specified in which group.
Notes Length of follow up not clear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Adequate
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Woittiez 1997
Methods Randomised controlled trial, allocation concealment by sealed opaque envelopes.
No information on blinding or loss to follow up.
Participants 60 patients who had developed hypoalbuminaemia (< 20g/l) after major surgery.
2 patients died after randomisation and before treatment started. They were excluded from the analysis
Interventions 1. saline (500ml/24 hr) (n = 16).
2. albumin 20% (300 ml/24h) (n = 15).
3. HES 10% (500ml/24h) for 3 days (n = 27).
Aim was to restore colloid osmotic pressure.
Outcomes Changes in fluid balance, serum albumin, COP and clinical signs of oedema were followed daily.
Death rates supplied by the author.
Notes Length of follow up unspecified.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Wu 2001
Methods Randomised controlled trial. No details given of randomisation method
Participants 41 adolescent or adult patients in emergency room suffering from shock
Interventions 1. 4% modified fluid gelatin: succinated gelatin 40g/L, sodium chloride 7g/L, sodium hydroxide 1.
36g/L (n = 18).
2. Lactated Ringer’s (n = 16).
Outcomes Death.
Haemodynamic variables.
Notes Not intention-to-treat: five patients who received blood transfusion and two who had surgery within the
first hour of resuscitation were dropped from the analysis.
Length of follow up not clear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Younes 1992
Methods Randomised “in a double blind fashion”.
Blinding by use of similar bottles.
No loss to follow up.
Participants Participants were emergency department admissions, who had a systolic blood pressure of less than
80mmHg and were 19 years and older.
Exclusions: pregnant, preexisting cardiac or metabolic disease
Interventions 1. 6% dextran 70 in 7.5% saline (n = 35).
2. 7.5% saline (n = 35).
3. 0.9% saline (n = 35).
Allocated fluid was for initial bolus of 250mL, followed by isotonic crystalloids as needed
Outcomes Deaths reported.
Fluid balance.
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Younes 1994
Methods Trial conducted in a “double blind randomised fashion”.
Blinding by use of coded, identical containers.
Participants Participants were trauma admissions to the emergency room requiring treatment for haemorrhagic hypo-
volaemia; all were over 15 years old.
Exclusions: pregnant, cardiac or renal failure, cardiac arrest on arrival
Interventions 1. 6% dextran 70 in 7.5% saline (n = 101).
2. 0.9% saline (n = 111).
Allocated fluid was for the first intravenous infusion only.
Outcomes Deaths reported.
Complications.
Notes Follow up period was 30 days.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Younes 1998
Methods Randomised controlled trial, allocation by sealed envelope. Blinding not mentioned, no apparent loss to
follow up
Participants Trauma patients with systolic blood pressure <90mmHg admitted to the emergency room, with no
previous treatment
Interventions 1. 10% pentastarch (n = 12).
2. 0.9% saline (n = 11).
Fluid given in 250mL boluses until systolic blood pressure > 100mmHg
Outcomes Deaths reported.
No complications reported in either group.
Notes Follow up to 24 hours.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
Zetterstrom 1981a
Methods The patients were randomly divided into two groups.
Allocation concealment was by sealed opaque envelopes (information supplied by author).
Blinding not mentioned.
No loss to follow up.
Participants Adult patients undergoing elective major abdominal surgery.
Interventions 1. Standard volume replacement regimen (1L Dextran 70 then up to 4 units of RBC with electrolyte,
then whole blood or RBC with plasma; post-op patients were given crystalloids and whole blood) plus
20% human albumin solution 100ml at end of operation, 200-300ml on same day, then 200ml on first
post-op day, then 100ml for next 3 days (n = 15).
2. Standard volume replacement regimen as above (n = 15).
Outcomes Deaths reported.
Haemodynamic variables.
Notes Length of follow up unspecified.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
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Zetterstrom 1981b
Methods The patients were randomly divided into two groups.
Allocation concealment was by sealed opaque envelopes (information supplied by author).
Blinding not mentioned.
No loss to follow up.
Participants 18 patients who had undergone elective abdominal aortic surgery.
No exclusions mentioned.
Interventions 1. 5% human albumin solution (n = 9).
2. Ringer’s lactate solution (n = 9).
Administration guided by pulmonary arterial occlusion pressure
Outcomes Deaths reported.
Haemodynamic variables.
Notes Follow up to discharge from hospital.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Unclear
COP = colloid osmotic pressure
HES = hydroxyethylstarch
LVEDP = left ventricular end diastolic pressure
LVEF = left ventricular ejection fraction
PAP = pulmonary artery pressure
PAWP = pulmonary artery wedge pressure
RBC = red blood cells
WP = wedge pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Artru 1989 Intervention to control intracranial pressure not directed at fluid resuscitation
Bocanegra 1966 This study contained two quasi-randomised comparisons of colloid with glucose and plasma/saline with
saline. In both studies, the control solution was only given IV if the patient was in coma or shock. It was
therefore not a reasonable comparison of colloid and crystalloid
Boldt 1996 All groups received some colloid.
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(Continued)
Boldt 2007 Comparison was not between colloids and crystalloids, rather two different colloid solutions
Bothner 1998 Participants were having minor elective surgery, therefore not considered to be critically ill
Breheme 1993 Intervention directed at haemodilution, not at volume replacement
Bueno R 2004 The participants had elective surgery.
Chin 2006 Participants were undergoing elective surgery, therefore not considered to be critically ill
Golub 1994 Albumin given solely as a nutritional supplement.
Goslinga 1992 Intervention directed at haemodilution, not volume replacement
Green 2008 Article is a review.
Greenhalgh 1995 Intervention directed at the maintenance of serum albumin levels, not for volume replacement
Hauser 1980 Cross-over trial.
Ko 2007 Comparison of crystalloids and colloids as preloading solutions
Krasheninnikov 2007 Not a randomised controlled trial.
Lagonidis 1995 Intervention was pre-loading for coronary artery bypass surgery
Lobo 2008 Experiment conducted on rabbits.
Marhofer 1999 Trial of fluid for preloading before spinal anaesthesia.
Mittermayr 2007 Patients were undergoing elective surgery.
Mittermayr 2008 Outcome was the change in concentration of tissue-type plasminogen activator
Niemi 2008 Solutions were used for pump priming.
Nilsson 1980 Albumin given as a nutritional supplement.
Oliviera 2002 The participants had sepsis.
Paton-Gay 2007 The outcome was non-relevant to comparing crystalloids and colloids
Paul 2003 The participants had elective surgery.
Rehm 2001 Two colloids (albumin and hetastarch) compared.
Steinberg 1989 Cross-over trial.
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(Continued)
Tiryakioglu 2008 Patients were undergoing elective surgery and not considered critically ill. Also, the solutions were used as
priming solutions
Tseng 2008 Crystalloid and colloid treatment was not randomised.
Valetova 2007 Patients were randomised depending upon their treatment not prior to treatment
Vercueil 2006 Article is a review.
Wilkes 2001 One group received saline plus hetastarch; the other received ’balanced’ fluid plus hetastarch. Thus, each
group received both a colloid and a crystalloid. This conflicts with the purpose our review which compares
patients who had one of these with patients who had the other
Woods 1993 This quasi-randomised trial looked at albumin supplementation in post operative patients, with the aim of
maintaining the serum albumin. Since the main aim of giving albumin was not to replace volume, the study
was excluded
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D A T A A N D A N A L Y S E S
Comparison 1. colloid versus crystalloid (add-on colloid)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 deaths 47 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 albumin or PPF 23 7754 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.92, 1.10]
1.2 hydroxyethyl starch 17 1172 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.96, 1.44]
1.3 modified gelatin 11 506 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.49, 1.72]
1.4 dextran 9 834 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.94, 1.65]
Comparison 2. colloid and hypertonic crystalloid versus isotonic crystalloid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 deaths 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 albumin or PPF 1 14 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.06, 4.33]
1.2 hydroxyethyl starch 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 modified gelatin 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.4 dextran 8 1283 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.74, 1.05]
Comparison 3. colloid versus hypertonic crystalloid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 deaths 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 albumin or PPF 1 38 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.39, 126.92]
1.2 hydroxyethyl starch 1 16 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 modified gelatin 1 20 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.4 dextran 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 colloid versus crystalloid (add-on colloid), Outcome 1 deaths.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients
Comparison: 1 colloid versus crystalloid (add-on colloid)
Outcome: 1 deaths
Study or subgroup colloid crystalloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 albumin or PPF
Boldt 1986 0/1 0/1 Not estimable
Boldt 1993 0/15 0/15 Not estimable
Boutros 1979 0/7 2/17 0.2 % 0.45 [ 0.02, 8.34 ]
Evans 2003 0/13 0/14 Not estimable
Gallagher 1985 0/5 0/5 Not estimable
Goodwin 1983 11/40 3/39 0.4 % 3.58 [ 1.08, 11.85 ]
Grundmann 1982 1/14 0/6 0.1 % 1.40 [ 0.06, 30.23 ]
Jelenko 1978 1/7 1/5 0.1 % 0.71 [ 0.06, 8.90 ]
Lowe 1977 3/77 4/94 0.5 % 0.92 [ 0.21, 3.97 ]
Lucas 1978 7/27 0/27 0.1 % 15.00 [ 0.90, 250.24 ]
Maitland 2005 2/56 11/61 1.4 % 0.20 [ 0.05, 0.85 ]
Metildi 1984 12/20 12/26 1.3 % 1.30 [ 0.75, 2.25 ]
Prien 1990 0/6 0/6 Not estimable
Rackow 1983 6/9 6/8 0.8 % 0.89 [ 0.48, 1.64 ]
SAFE 2004 726/3473 729/3460 93.7 % 0.99 [ 0.91, 1.09 ]
Shah 1977 2/9 3/11 0.3 % 0.81 [ 0.17, 3.87 ]
Shires 1983 0/9 0/9 Not estimable
Tollofsrud 1995 0/10 1/10 0.2 % 0.33 [ 0.02, 7.32 ]
Verheij 2006 0/18 0/16 Not estimable
Virgilio 1979 1/15 1/14 0.1 % 0.93 [ 0.06, 13.54 ]
Woittiez 1997 8/15 4/16 0.5 % 2.13 [ 0.81, 5.64 ]
Zetterstrom 1981a 0/15 1/15 0.2 % 0.33 [ 0.01, 7.58 ]
Zetterstrom 1981b 2/9 0/9 0.1 % 5.00 [ 0.27, 91.52 ]
Subtotal (95% CI) 3870 3884 100.0 % 1.01 [ 0.92, 1.10 ]
Total events: 782 (colloid), 778 (crystalloid)
0.01 0.1 1 10 100
favours colloid favours crystalloid
(Continued . . . )
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(. . . Continued)
Study or subgroup colloid crystalloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 18.61, df = 15 (P = 0.23); I2 =19%
Test for overall effect: Z = 0.16 (P = 0.87)
2 hydroxyethyl starch
Boldt 1993 0/30 0/15 Not estimable
Boldt 2001 0/50 0/25 Not estimable
Brunkhorst 2008 107/261 93/274 82.1 % 1.21 [ 0.97, 1.51 ]
Cifra 2003 1/11 3/13 2.5 % 0.39 [ 0.05, 3.27 ]
Dehne 2001 0/45 0/15 Not estimable
Fries 2004 0/20 0/20 Not estimable
Guo 2003 0/20 0/20 Not estimable
Lang 2001 0/21 0/21 Not estimable
Lang 2003 0/18 0/18 Not estimable
Moretti 2003 0/60 0/30 Not estimable
Nagy 1993 2/21 2/20 1.9 % 0.95 [ 0.15, 6.13 ]
Prien 1990 1/6 0/6 0.5 % 3.00 [ 0.15, 61.74 ]
Rackow 1983 5/9 6/8 5.7 % 0.74 [ 0.36, 1.50 ]
Sirieix 1999 0/8 0/8 Not estimable
Verheij 2006 0/17 0/16 Not estimable
Woittiez 1997 13/27 4/16 4.5 % 1.93 [ 0.76, 4.90 ]
Younes 1998 2/12 3/11 2.8 % 0.61 [ 0.12, 3.00 ]
Subtotal (95% CI) 636 536 100.0 % 1.18 [ 0.96, 1.44 ]
Total events: 131 (colloid), 111 (crystalloid)
Heterogeneity: Chi2 = 4.86, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
3 modified gelatin
Boldt 1993 0/15 0/15 Not estimable
Boldt 2001 0/25 0/25 Not estimable
Evans 1996 1/11 2/14 11.3 % 0.64 [ 0.07, 6.14 ]
Evans 2003 0/14 0/14 Not estimable
Fries 2004 0/20 0/20 Not estimable
Ngo 2001 0/56 0/111 Not estimable
Tollofsrud 1995 0/10 1/10 9.6 % 0.33 [ 0.02, 7.32 ]
Upadhyay 2004 9/29 9/31 55.6 % 1.07 [ 0.49, 2.32 ]
Verheij 2006 1/16 0/16 3.2 % 3.00 [ 0.13, 68.57 ]
0.01 0.1 1 10 100
favours colloid favours crystalloid
(Continued . . . )
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(. . . Continued)
Study or subgroup colloid crystalloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wahba 1996 0/10 0/10 Not estimable
Wu 2001 2/18 3/16 20.3 % 0.59 [ 0.11, 3.11 ]
Subtotal (95% CI) 224 282 100.0 % 0.91 [ 0.49, 1.72 ]
Total events: 13 (colloid), 15 (crystalloid)
Heterogeneity: Chi2 = 1.48, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
4 dextran
Dawidson 1991 1/10 1/10 1.5 % 1.00 [ 0.07, 13.87 ]
Hall 1978 18/86 16/86 24.7 % 1.13 [ 0.62, 2.06 ]
Karanko 1987 0/14 1/18 2.0 % 0.42 [ 0.02, 9.64 ]
Modig 1983 0/14 0/17 Not estimable
Ngo 2001 0/55 0/111 Not estimable
Tollofsrud 1995 0/10 1/10 2.3 % 0.33 [ 0.02, 7.32 ]
Vassar 1993a 21/89 11/85 17.4 % 1.82 [ 0.94, 3.55 ]
Vassar 1993b 49/99 20/50 41.1 % 1.24 [ 0.83, 1.83 ]
Younes 1992 7/35 7/35 10.8 % 1.00 [ 0.39, 2.55 ]
Subtotal (95% CI) 412 422 100.0 % 1.24 [ 0.94, 1.65 ]
Total events: 96 (colloid), 57 (crystalloid)
Heterogeneity: Chi2 = 2.76, df = 6 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
0.01 0.1 1 10 100
favours colloid favours crystalloid
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Analysis 2.1. Comparison 2 colloid and hypertonic crystalloid versus isotonic crystalloid, Outcome 1 deaths.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients
Comparison: 2 colloid and hypertonic crystalloid versus isotonic crystalloid
Outcome: 1 deaths
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 albumin or PPF
Jelenko 1978 1/7 2/7 100.0 % 0.50 [ 0.06, 4.33 ]
Subtotal (95% CI) 7 7 100.0 % 0.50 [ 0.06, 4.33 ]
Total events: 1 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 hydroxyethyl starch
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 modified gelatin
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 dextran
Chavez-Negrete 1991 1/26 5/23 2.9 % 0.18 [ 0.02, 1.41 ]
Mattox 1991 35/211 42/211 22.6 % 0.83 [ 0.56, 1.25 ]
Vassar 1990 12/23 13/24 6.8 % 0.96 [ 0.56, 1.65 ]
Vassar 1991 30/83 34/83 18.3 % 0.88 [ 0.60, 1.30 ]
Vassar 1993a 21/89 14/84 7.7 % 1.42 [ 0.77, 2.60 ]
Vassar 1993b 49/99 23/45 17.0 % 0.97 [ 0.68, 1.37 ]
Younes 1992 7/35 8/35 4.3 % 0.88 [ 0.36, 2.15 ]
Younes 1994 27/101 40/111 20.5 % 0.74 [ 0.49, 1.11 ]
Subtotal (95% CI) 667 616 100.0 % 0.88 [ 0.74, 1.05 ]
Total events: 182 (Treatment), 179 (Control)
Heterogeneity: Chi2 = 5.79, df = 7 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 3.1. Comparison 3 colloid versus hypertonic crystalloid, Outcome 1 deaths.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill patients
Comparison: 3 colloid versus hypertonic crystalloid
Outcome: 1 deaths
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 albumin or PPF
Bowser-Wallace 1986 3/19 0/19 100.0 % 7.00 [ 0.39, 126.92 ]
Subtotal (95% CI) 19 19 100.0 % 7.00 [ 0.39, 126.92 ]
Total events: 3 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 hydroxyethyl starch
Sirieix 1999 0/8 0/8 Not estimable
Subtotal (95% CI) 8 8 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 modified gelatin
Mazher 1998 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 dextran
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Injuries Group’s Specialised Register (searched 30 Sept 2008), PubMed (searched 30 September; last three months),
Controlled Trials metaRegister (www.controlled-trials.com) (searched 30 Sept 2008)
colloid* or hydrocolloid* or crystalloid*
MEDLINE 1950 to Sept 2008, EMBASE 1980 to Sept 2008
1.exp Fluid Therapy/
2.exp Rehydration Solutions/
3.exp Colloids/
4.exp Plasma Substitutes/
5.exp Plasma/
6.exp Serum/
7.exp Albumins/
8.exp Isotonic Solutions/
9.exp Hetastarch/
10.((fluid$ or volume or plasma or rehydrat$ or blood or oral) adj3 (replace$ or therap$ or substitut$ or restorat$ or resuscitat$ or
rehydrat$)).ab,ti.
11.((fluid$ or volume or plasma or rehydrat$ or blood or oral) adj3 (challenge or perfusion or volume or intravenous or shock)).ti,ab.
12.(isotonic saline solution$ or Blood substitute$ or blood expander$ or plasma volume expander$ or volume expander$).mp. [mp=
title, original title, abstract, name of substance word, subject heading word]
13.(colloid$ or crystalloid$ or albumin$ or albumen$ or plasma$ or starch$ or dextran$ or gelofus$ or hemaccel$ or haemaccel$ or
hydrocolloid$ or serum$ or hetastarch or isotonic or ringer$ or gelatin$ or gentran$ or pentastarch$ or pentaspan$ or hartman or
sodium or potassium or salin$ or hypertonic or hypotonic or hemodilution or haemodilution or ringer lactatae).ti.
14.or/1-13
15.randomi?ed.ab.
16.randomized controlled trial.pt.
17.controlled clinical trial.pt.
18.placebo.ab.
19.clinical trials as topic.sh.
20.randomly.ab.
21.trial.ti.
22.or/15-21
23.humans.sh.
24.22 and 23
25.14 and 24
26.colloid* or hydrocolloid* or crystalloid*
27.exp Colloids/
28.26 or 27
29.25 and 28
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to Sept 2008, ISI Web of Science: Conference
Proceedings Citation Index- Science (CPCI-S) 1990 to Sept 2008
Topic=(colloid* or hydrocolloid*) AND Topic=(crystalloid*) AND Topic=(randomised OR randomized OR randomly OR random
order OR random sequence OR random allocation OR randomly allocated OR at random OR randomized controlled trial* OR
controlled clinical trial* OR randomized controlled trial*) NOT Topic=(animal model* OR Animal* OR Animal Experiment* OR
Animal disease model* OR Laboratory Animal*)
CENTRAL (The Cochrane Library Issue 3, 2008), National Research Register (to 2006, Issue 4)
#1MeSH descriptor Albumins explode all trees
#2MeSH descriptor Plasma Substitutes explode all trees
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#3MeSH descriptor Plasma explode all trees
#4MeSH descriptor Plasma Volume explode all trees
#5MeSH descriptor Fluid Therapy explode all trees
#6MeSH descriptor Colloids explode all trees
#7(#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8(crystalloid* or ringer* or hartman* or sodium* or potassium* or salin*):ti or (crystalloid* or ringer* or hartman* or sodium* or
potassium* or salin*):ab
#9Isotonic saline solution* OR Blood substitute* OR blood expander* OR plasma volume expander* OR volume expander*
#10(colloid* OR crystalloid* OR albumin* OR albumen* OR plasma OR starch* OR dextran* OR gelofus* OR hemaccel* OR
haemaccel* OR OR serum OR hetastarch OR isotonic OR ringer* OR gelatin* OR gentran* OR pentastarch* OR pentaspan* OR
hartman OR sodium OR potassium OR saline):ti
#11(fluid* OR volume OR plasma OR rehydrat* OR blood OR oral) AND (replace* OR therapy OR substitut* OR restorat* OR
resuscitat* OR rehydrat*):ab
#12MeSH descriptor Rehydration Solutions explode all trees
#13MeSH descriptor Serum explode all trees
#14MeSH descriptor Isotonic Solutions explode all trees
#15MeSH descriptor Hetastarch explode all trees
#16(#1 OR #2 OR #2 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17MeSH descriptor Colloids explode all trees
#18colloid* OR crystalloid* OR hydrocolloid*
#19#17 OR #18
#20#16 AND #19
WH A T ’ S N E W
Last assessed as up-to-date: 29 September 2008.
Date Event Description
17 April 2009 New search has been performed April 2009
An updated search for new trials was conducted in October 2008. One new study
was included (Brunkhorst 2008). The analysis, results and discussion sections
have been revised accordingly
H I S T O R Y
Protocol first published: Issue 4, 1997
Review first published: Issue 4, 1997
Date Event Description
16 July 2008 Amended Converted to new review format.
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(Continued)
1 July 2007 New search has been performed August 2007
An updated search for new trials was conducted in December 2006. Ten new
studies were included (Evans 2003, Cifra 2003, Fries 2004, Guo 2003, Lang 2003,
Maitland 2005, Moretti 2003, Upadhyay 2004, Verheij 2006, Wills 2005). The
analysis, results and discussion sections have been revised accordingly
C O N T R I B U T I O N S O F A U T H O R S
July 2007
PP and IR examined trials for inclusion or exclusion, reaching agreement by discussion. PP and IR extracted data from the new studies.
PP amended the text of the review.
April 2009
IR andMP examined trials for inclusion or exclusion, reaching agreement by discussion. IR and MP extracted data from the new study.
MP amended the text of the review. PP edited the final version.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Institute of Child Health, University of London, UK.
• UK Cochrane Centre, NHS R&D Programme, UK.
External sources
• NHS R&D Programme: Mother and Child Health, UK.
• Cochrane Review Incentive Scheme, Department of Health, UK.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
∗Rehydration Solutions; Colloids [∗therapeutic use]; Critical Illness [∗therapy]; Fluid Therapy [∗methods]; Plasma Substitutes
[∗therapeutic use]; Randomized Controlled Trials as Topic; Resuscitation [methods]
MeSH check words
Humans
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